Literature DB >> 34515874

Metabolic Regulation of Glia and Their Neuroinflammatory Role in Alzheimer's Disease.

Kumari Preeti1, Anika Sood2, Valencia Fernandes2.   

Abstract

Alzheimer's disease (AD) is an aging-related neurodegenerative disorder. It is characterized clinically by progressive memory loss and impaired cognitive function. Its progression occurs from neuronal synapse loss to amyloid pathology and Tau deposit which eventually leads to the compromised neuronal function. Neurons in central nervous tissue work in a composite and intricate network with the glia and vascular cells. Microglia and astrocytes are becoming the prime focus due to their involvement in various aspects of neurophysiology, such as trophic support to neurons, synaptic modulation, and brain surveillance. AD is also often considered as the sequela of prolonged metabolic dyshomeostasis. The neuron and glia have different metabolic profiles as cytosolic glycolysis and mitochondrial-dependent oxidative phosphorylation (OXPHOS), especially under dyshomeostasis or with aging pertaining to their unique genetic built-up. Various efforts are being put in to decipher the role of mitochondrial dynamics regarding their trafficking, fission/fusion imbalance, and mitophagy spanning over both neurons and glia to improve aging-related brain health. The mitochondrial dysfunction may lead to activation in various signaling mechanisms causing metabolic reprogramming in glia cells, further accelerating AD-related pathogenic events. The glycolytic-dominant astrocytes switch to the neurotoxic phenotype, i.e., disease-associated astrocyte under metabolic stress. The microglia also transform from resting to reactive phenotype, i.e., disease-associated microglia. It may also exist in otherwise a misconception an M1, glycolytic, or M2, an OXPHOS-dependent phenotype. Further, glial transformation plays a vital role in regulating hallmarks of AD pathologies like synapse maintenance, amyloid, and Tau clearance. In this updated review, we have tried to emphasize the metabolic regulation of glial reactivity, mitochondrial quality control mechanisms, and their neuroinflammatory response in Alzheimer's progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aging; Amyloid; Bioenergetics; Immunity; Metabolic reprogramming; Synapse; Tau

Mesh:

Year:  2021        PMID: 34515874     DOI: 10.1007/s10571-021-01147-7

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  134 in total

1.  Mitochondrial dynamics--mitochondrial fission and fusion in human diseases.

Authors:  Stephen L Archer
Journal:  N Engl J Med       Date:  2013-12-05       Impact factor: 91.245

Review 2.  Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease.

Authors:  C R Abraham
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

3.  Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.

Authors:  G W Arendash; W Schleif; K Rezai-Zadeh; E K Jackson; L C Zacharia; J R Cracchiolo; D Shippy; J Tan
Journal:  Neuroscience       Date:  2006-08-28       Impact factor: 3.590

4.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

Review 5.  Cell Biology of Astrocyte-Synapse Interactions.

Authors:  Nicola J Allen; Cagla Eroglu
Journal:  Neuron       Date:  2017-11-01       Impact factor: 17.173

6.  A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease.

Authors:  Sung Hoon Baik; Seokjo Kang; Woochan Lee; Hayoung Choi; Sunwoo Chung; Jong-Il Kim; Inhee Mook-Jung
Journal:  Cell Metab       Date:  2019-06-27       Impact factor: 27.287

7.  The mixture of "ecstasy" and its metabolites impairs mitochondrial fusion/fission equilibrium and trafficking in hippocampal neurons, at in vivo relevant concentrations.

Authors:  Daniel José Barbosa; Romàn Serrat; Serena Mirra; Martí Quevedo; Elena Goméz de Barreda; Jesús Àvila; Luísa Maria Ferreira; Paula Sério Branco; Eduarda Fernandes; Maria de Lourdes Bastos; João Paulo Capela; Eduardo Soriano; Félix Carvalho
Journal:  Toxicol Sci       Date:  2014-03-04       Impact factor: 4.849

8.  A Metabolic Shift toward Pentose Phosphate Pathway Is Necessary for Amyloid Fibril- and Phorbol 12-Myristate 13-Acetate-induced Neutrophil Extracellular Trap (NET) Formation.

Authors:  Estefania P Azevedo; Natalia C Rochael; Anderson B Guimarães-Costa; Thiago S de Souza-Vieira; Juliana Ganilho; Elvira M Saraiva; Fernando L Palhano; Debora Foguel
Journal:  J Biol Chem       Date:  2015-07-21       Impact factor: 5.157

9.  Astrocytes protect neurons from Aβ1-42 peptide-induced neurotoxicity increasing TFAM and PGC-1 and decreasing PPAR-γ and SIRT-1.

Authors:  Diana Aguirre-Rueda; Sol Guerra-Ojeda; Martin Aldasoro; Antonio Iradi; Elena Obrador; Angel Ortega; M Dolores Mauricio; Jose Ma Vila; Soraya L Valles
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

10.  Microglial identity and inflammatory responses are controlled by the combined effects of neurons and astrocytes.

Authors:  Paul S Baxter; Owen Dando; Katie Emelianova; Xin He; Sean McKay; Giles E Hardingham; Jing Qiu
Journal:  Cell Rep       Date:  2021-03-23       Impact factor: 9.423

View more
  3 in total

Review 1.  Glucose Metabolism, Neural Cell Senescence and Alzheimer's Disease.

Authors:  Qianqian Wang; Linyan Duan; Xingfan Li; Yifu Wang; Wenna Guo; Fangxia Guan; Shanshan Ma
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

Review 2.  Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer's disease.

Authors:  Yun Li; Xiaohuan Xia; Yi Wang; Jialin C Zheng
Journal:  J Neuroinflammation       Date:  2022-10-06       Impact factor: 9.587

3.  The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer's Disease.

Authors:  Kirsten L Viola; Maira A Bicca; Adrian M Bebenek; Daniel L Kranz; Vikas Nandwana; Emily A Waters; Chad R Haney; Maxwell Lee; Abhay Gupta; Zachary Brahmbhatt; Weijian Huang; Ting-Tung Chang; Anderson Peck; Clarissa Valdez; Vinayak P Dravid; William L Klein
Journal:  Front Neurosci       Date:  2022-01-03       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.